-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

Benzinga·07/23/2026 16:12:03
语音播报
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.